Stockscreener 앱 받기
83.08
0.95%
0.78
시장 영업 전:
83.11
0.03
+0.04%
Protagonist Therapeutics Inc 주식(PTGX)의 최신 뉴스
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) Insider Sells 5,000 Shares of Stock - MarketBeat
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) Insider Sells 13,151 Shares of Stock - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) CFO Asif Ali Sells 46,203 Shares - MarketBeat
Protagonist Therapeutics CEO Patel sells $4m in shares By Investing.com - Investing.com India
Protagonist Therapeutics chief medical officer sells $1.9m in shares By Investing.com - Investing.com Canada
Protagonist Therapeutics CEO Patel sells $4m in shares - Investing.com
VIX Spike: Can Protagonist Therapeutics Inc weather a recessionStop Loss & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Universal Beteiligungs und Servicegesellschaft mbH Raises Stock Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Technical Reactions to PTGX Trends in Macro Strategies - Stock Traders Daily
Have Insiders Sold Protagonist Therapeutics Shares Recently? - Sahm
Earnings Risk: Will Protagonist Therapeutics Inc benefit from AI trendsAnalyst Downgrade & Daily Market Momentum Tracking - baoquankhu1.vn
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - citizen-times.com
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026 - southbendtribune.com
Analysts Are Bullish on These Healthcare Stocks: Protagonist Therapeutics (PTGX), CG Oncology, Inc. (CGON) - The Globe and Mail
Protagonist therapeutics CMO Molina sells $784k in shares By Investing.com - Investing.com Canada
Protagonist therapeutics CEO Patel sells $2.84 million in shares By Investing.com - Investing.com India
Asif Ali Sells 8,588 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Insider Arturo Md Molina Sells 9,514 Shares - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $2,840,446.24 in Stock - MarketBeat
Protagonist therapeutics CEO Patel sells $2.84 million in shares - Investing.com
Protagonist Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView
US Market Wrap: Is Protagonist Therapeutics Inc trading at a discount2025 Bull vs Bear & Free Community Consensus Stock Picks - baoquankhu1.vn
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025 - FinancialContent
Earnings Report: Is Protagonist Therapeutics Inc stock good for income investorsQuarterly Investment Review & AI Based Buy and Sell Signals - baoquankhu1.vn
H.C. Wainwright Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX) - The Globe and Mail
Aug Macro: Can Protagonist Therapeutics Inc expand into new marketsM&A Rumor & Weekly Momentum Picks - baoquankhu1.vn
Aug Action: Is BIOX a strong growth stockWeekly Trend Report & Verified Stock Trade Ideas - baoquankhu1.vn
Risk On: Should I add GPUS stock to my portfolio2025 EndofYear Setup & Weekly High Potential Stock Alerts - baoquankhu1.vn
Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis - news-journalonline.com
With Two Partnered Launches Expected In 2026, Protagonist Looks To Next Chapter - Citeline News & Insights
SG Americas Securities LLC Grows Stock Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Market Fear: Can Protagonist Therapeutics Inc sustain its profitabilityPortfolio Value Summary & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Trading the Move, Not the Narrative: (PTGX) Edition - Stock Traders Daily
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? - 富途资讯
Day Trade: Can Protagonist Therapeutics Inc expand into new marketsJuly 2025 Sector Moves & Intraday High Probability Setup Alerts - baoquankhu1.vn
Fundamentals Check: Is Protagonist Therapeutics Inc stock a falling knife or bargain buyShare Buyback & Stepwise Trade Signal Implementation - baoquankhu1.vn
Protagonist Therapeutics, Inc Updates on Clinical Developments and Collaborations - TradingView — Track All Markets
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting - greenvilleonline.com
Is Protagonist Therapeutics Inc. stock overvalued by current metricsWeekly Risk Report & Verified Momentum Watchlists - ulpravda.ru
Is Protagonist Therapeutics Inc. stock a contrarian buy2025 Investor Takeaways & Reliable Entry Point Alerts - Улправда
Protagonist Therapeutics, Inc.Common Stock (NQ: PTGX - FinancialContent
Can Protagonist Therapeutics Inc. stock rebound after recent weaknessWatch List & AI Driven Stock Reports - Улправда
History Review: How Protagonist Therapeutics Inc. stock benefits from strong dollarJuly 2025 Snapshot & Daily Volume Surge Signals - Улправда
Will Protagonist Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Chart Watch & Accurate Intraday Trade Tips - Улправда
Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 119% One-Year Surge? - Yahoo Finance
Protagonist Therapeutics Advances Pipeline Amid Financial Loss - MSN
2.09%
0.48%
자본화:
|
볼륨(24시간):